Title A Phase I Clinical Trial of mTOR Inhibition with Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Contact FS
Principal Investigator Adekunle Odunsi, MD PhD
Study Number 199911
Phase1
Summary
The purpose of this research is to study a vaccine treatment called recombinant canarypox-NY-ESO-1/TRICOM [also called ALVAC(2)-NY-ESO(M)/TRICOM]. The study is limited to patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express certain proteins (antigens) called NY-ESO-1 or LAGE-1. A vaccine is a medicine that teaches the immune system in the body to destroy harmful infections or cancer cells that do not belong in the normal tissues.
Eligibility
Please Click on link for ClinicalTrials.gov for eligibility criteria.